新里程：三季度亏损主要原因是独一味制药受集采冲击较大

Core Viewpoint - The company reported a significant loss in the third quarter primarily due to the impact of centralized procurement on its product, Du Yi Wei [2] Group 1: Financial Performance - The third quarter loss was mainly attributed to the substantial impact of centralized procurement on Du Yi Wei Pharmaceutical [2] - The execution and implementation period of centralized procurement after winning bids at the beginning of the year led to a decline in sales during the execution phase [2] - The price drop resulting from the centralized procurement directly affected the company's financial performance, with the peak impact observed in the third quarter due to settlement delays [2] Group 2: Market Recovery Efforts - As of September, sales of Du Yi Wei products have shown signs of recovery after a period of decline [2] - The company is actively responding to the market situation post-centralized procurement by focusing on restoring growth in existing markets [2] - Additionally, the company is increasing efforts to develop untapped regions, aiming for a rebound in performance [2]